Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands.
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.
针对诊断算法的重大变化和各种大型临床试验的成熟结果的公布,欧洲神经肿瘤学会(EANO)认识到有必要为成人弥漫性神经胶质瘤患者的诊断和管理提供更新的指南。通过这些循证指南,EANO 的一个工作组为成人弥漫性神经胶质瘤患者的诊断、治疗和随访提供了建议。诊断部分基于 2016 年世界卫生组织中枢神经系统肿瘤分类的更新以及随后的通知 Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW) 的建议。关于治疗,我们根据最新改变实践的临床试验的结果制定了建议,并且还为神经病理学和神经放射学评估提供了指导。在这些指南中,我们定义了手术、放疗和系统药物治疗的主要治疗方式的作用,涵盖了当前的进展,并认识到应该避免不必要的干预和费用。本文件旨在为参与成人弥漫性神经胶质瘤患者管理的专业人员、患者和护理人员以及医疗保健提供者提供参考来源。